BioWorld

May 16, 2007

View Archived Issues

CMS Cites EPO's Bad Rap In Plan To Curtail Reimbursement

Sales of Amgen Inc.'s blockbuster EPO products are facing a further downturn, this time thanks to the Centers for Medicare & Medicaid Services (CMS), and the company's stock on Tuesday lost 3.7 percent as a result. (BioWorld Today) Read More

Intrexon Follows RheoGene Merger With $25M Series C1

Read More

Modigene Financing Garners $11.6M; High Hopes For CTP

Read More

CV Therapeutics Files NDA For Regadenoson Use In Stress Tests

Read More

Marcadia Raises $15M In First Round For Metabolic Programs

Read More

Other News To Note

Read More

Clinic Roundup

Read More